Beta-thalassemia intermedia

Beta-thalassemia intermedia: Description, Causes and Risk Factors:-thalassemia intermedia.Beta-thalassemia intermedia is an inherited blood disease that affects hemoglobin, the major component of red blood cells which carry oxygen through the body. Hemoglobin is made up of two different oxygen-carrying proteins, alpha and beta. People with beta-thalassemia intermedia do not produce enough beta protein — and in some cases do not produce it at all — resulting in a shortage of red blood cells, a condition known as anemia. Without sufficient numbers of properly functioning red blood cells, the organs of the body do not receive enough oxygen.The disease is most common in people of Mediterranean descent, especially in those from Sardinia and Cyprus. In Cyprus, 1 in 7 people are carriers of the disease, a rate which prompted a successful government-run prevention program there. Beta-thalassemia intermedia is also commonly found in the Middle East and Asia.Beta-thalassemia intermedia is the result of deficient or absent synthesis of beta globin chains, leading to excess alpha chains. Beta globin synthesis is controlled by one gene on each chromosome 11. Beta thalassemia intermedia occur from any of more than 200 point mutations and (rarely) deletions of the two genes. Beta globin chain production can range from near normal to completely absent, leading to varying degrees of excess alpha globin to beta globin chain production. The one gene defect, beta thalassemia trait (minor), is asymptomatic and results in microcytosis and mild anemia. If the synthesis from both genes is severely reduced or absent, the person has beta thalassemia major, also known as Cooley anemia. Persons with beta-thalassemia intermedia major are almost never symptomatic at birth because of the presence of HbF, but symptoms begin to develop by six months of age. If the synthesis of beta chains is less severely reduced, the person has beta thalassemia intermedia. These persons experience symptoms that are less severe and do not require lifelong transfusions to survive past 20 years of age.Beta-thalassemia intermediaSymptoms:Some people are "silent carriers" of beta-thalassemia intermedia and do not have any symptoms. People who are silent carriers have beta thalassemia trait. They often have mild anemia, which is only diagnosed through a blood test.Other symptoms may include:Fatigue and weakness.
  • Pale skin or jaundice (yellowing of the skin).
  • Protruding abdomen with enlarged spleen and liver.
  • Dark urine.
  • Cholelithiasis.
  • Moderate to severe skeletal changes.
  • Extramedullary masses of hyperplastic erythroid marrow.
  • Abnormal facial bones and poor growth.
  • A poor appetite.
Diagnosis:Commonly occurring mutations of the HBB gene are detected by a number of polymerase chain reaction (PCR)-based procedures. The most commonly used methods are reverse dot blot analysis or primer-specific amplification with a set of probes or primers complementary to the most common mutations in the population from which the affected individual originated.Other methods based on real-time PCR or microarray technology because of their reproducibility, rapidity, and easy handling are potentially suitable for the routine clinical laboratory.If targeted mutation analysis fails to detect the mutation, scanning or sequence analysis can be used. Sensitivity of both mutation scanning and sequence analysis is 99%. In the meantime, the presence of an extended deletion should be investigated by using multiplex ligation-dependent probe amplification (MPLA).Treatment:The most common treatment of beta-thalassemia intermedia is blood transfusions, which provide a temporary supply of healthy red blood cells to bring oxygen to the body. Among people with thalassemia major, transfusions may take place every two to three weeks. While these transfusions can be life-saving and life-enhancing, they result in a toxic buildup of iron in the blood. To counteract this side-effect, people with beta thalassemia intermedia require a procedure called chelation therapy in which a medication is taken to eliminate excess iron from the body. These individuals require frequent monitoring by a physician to assess the efficacy of transfusion/chelation therapy.In a small minority of people, a bone marrow transplant from a sibling or other suitable donor has been able to cure the disease. This procedure, however, is risky and could even be fatal.NOTE: The above information is educational purpose. The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition.DISCLAIMER: This information should not substitute for seeking responsible, professional medical care.


Submit a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Cart Preview

Rate This:

[Total: 0    Average: 0/5]
ADHD Symptoms in Teens Linked to Intensive Social Media Use

ADHD Symptoms in Teens Linked to Intensive Social Media Use

A new study, published in the medical journal JAMA, finds that the more teenagers involved in social media, the higher their risk is to develop the symptoms of attention deficit hyperactivity disorder (ADHD). These symptoms may include inattention, hyperactivity,...

Your Blood Type Determines the Risk of Being Attacked by Ticks

Your Blood Type Determines the Risk of Being Attacked by Ticks

Scientists from the Check Republic discovered the evidence that ticks may prefer attacking people with a certain blood type. Tick, the blood-sucking parasites, can carry various bacteria, including bugs that cause the Lyme disease. In the course of study, the...

[WpProQuiz 1]

Featured Products

How to Choose the Right Sport for You?

We all know that doing sports is very important, both for health and for a beautiful body. But at the moment when we decide to finally take the path, we are faced with the question: what kind of sport is right for me? So, let's start with the fact that a lot of people...

read more